help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Published ahead of print on June 16, 2005, doi:10.1164/rccm.200504-531OE

Am. J. Respir. Crit. Care Med., Volume 172, Number 5, September 2005, 523-529

A more recent version of this article appeared on September 1, 2005
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
200504-531OEv1
172/5/523    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spiro, S. G
Right arrow Articles by Silvestri, G. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spiro, S. G
Right arrow Articles by Silvestri, G. A

Submitted on April 5, 2005
Accepted on May 25, 2005

100 Years of Lung Cancer

Stephen G Spiro1* and Gerard A Silvestri2

1 Department of Thoracic Medicine, Middlesex Hospital, London, UK, 2 Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston, SC, USA

* To whom correspondence should be addressed. E-mail: stephen.spiro{at}uclh.org.

A hundred years ago lung cancer was a reportable disease which has now risen to be the commonest cause of death from cancer in both men and women in the developed world, and before long in the developing world as well. The disease has no particular symptoms or signs for its detection at an early stage. Most patients therefore present with advanced stage IIIB or IV disease. Screening tests began in the 1950's with annual chest x-ray and sputum cytology but found no improvement in overall mortality compared to control subjects. The same question is now being asked of spiral low dose CT scanning. There have been big refinements in the staging classification of lung cancer and advances in stage identification using minimally invasive technology. Post surgical mortality has declined from the early days of the 1950s but 5 year cure rates have only barely improved. The addition of chemotherapy to radical radiotherapy, together with novel radiotherapy techniques is gradually improving the outcome for locally advanced inoperable non-small cell lung cancer (NSCLC). Chemotherapy offers modest survival improvement for patients with NSCLC, the modern agents being better tolerated resulting in an improved quality of life. The management of small cell lung cancer which appeared so promising at the beginning of the 1970's has hit a plateau with little advance in outcome over the last 15 years. The most important and cost effective management for lung cancer is smoking cessation but for those with the disease novel agents and treatment approaches are urgently needed.
Key words: Lung Cancer, history, staging, treatment




This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
M. Infante, S. Cavuto, F. R. Lutman, G. Brambilla, G. Chiesa, G. Ceresoli, E. Passera, E. Angeli, M. Chiarenza, G. Aranzulla, et al.
A Randomized Study of Lung Cancer Screening with Spiral Computed Tomography: Three-year Results from the DANTE Trial
Am. J. Respir. Crit. Care Med., September 1, 2009; 180(5): 445 - 453.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
X. Tong, K. Li, Z. Luo, B. Lu, X. Liu, T. Wang, M. Pang, B. Liang, M. Tan, M. Wu, et al.
Decreased TIP30 Expression Promotes Tumor Metastasis in Lung Cancer
Am. J. Pathol., May 1, 2009; 174(5): 1931 - 1939.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
G. Pelosi and J. Rosai
Invited Commentary
Ann. Thorac. Surg., October 1, 2008; 86(4): 1090 - 1091.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Zheng, S. E. Morgan-Lappe, J. Yang, K. M. Bockbrader, D. Pamarthy, D. Thomas, S. W. Fesik, and Y. Sun
Growth Inhibition and Radiosensitization of Glioblastoma and Lung Cancer Cells by Small Interfering RNA Silencing of Tumor Necrosis Factor Receptor-Associated Factor 2
Cancer Res., September 15, 2008; 68(18): 7570 - 7578.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
B. P. van Putte, M. Grootenboers, W.-J. van Boven, J. M. H. Hendriks, P. E. Y. van Schil, G. Guetens, G. De Boeck, G. Pasterkamp, F. Schramel, and G. Folkerts
Pharmacokinetics of Gemcitabine when Delivered by Selective Pulmonary Artery Perfusion for the Treatment of Lung Cancer
Drug Metab. Dispos., April 1, 2008; 36(4): 676 - 681.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. I. Na, B. H. Byun, H. J. Kang, G. J. Cheon, J. S. Koh, C. H. Kim, D. H. Choe, B.-Y. Ryoo, J. C. Lee, S. M. Lim, et al.
18F-Fluoro-2-Deoxy-Glucose Uptake Predicts Clinical Outcome in Patients with Gefitinib-Treated Non-Small Cell Lung Cancer
Clin. Cancer Res., April 1, 2008; 14(7): 2036 - 2041.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
G. Sharma, J. Freeman, D. Zhang, and J. S. Goodwin
Trends in End-of-Life ICU Use Among Older Adults With Advanced Lung Cancer
Chest, January 1, 2008; 133(1): 72 - 78.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
C. Nahmias, W. T. Hanna, L. M. Wahl, M. J. Long, K. F. Hubner, and D. W. Townsend
Time Course of Early Response to Chemotherapy in Non-Small Cell Lung Cancer Patients with 18F-FDG PET/CT
J. Nucl. Med., May 1, 2007; 48(5): 744 - 751.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Kunnimalaiyaan and H. Chen
Tumor Suppressor Role of Notch-1 Signaling in Neuroendocrine Tumors
Oncologist, May 1, 2007; 12(5): 535 - 542.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. K. Rho, Y. J. Choi, B.-Y. Ryoo, I. I. Na, S. H. Yang, C. H. Kim, and J. C. Lee
p53 Enhances Gefitinib-Induced Growth Inhibition and Apoptosis by Regulation of Fas in Non-Small Cell Lung Cancer
Cancer Res., February 1, 2007; 67(3): 1163 - 1169.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
X.-c. Chen, R. Wang, X. Zhao, Y.-q. Wei, M. Hu, Y.-s. Wang, X.-w. Zhang, R. Zhang, L. Zhang, B. Yao, et al.
Prophylaxis against carcinogenesis in three kinds of unestablished tumor models via IL12-gene-engineered MSCs
Carcinogenesis, December 1, 2006; 27(12): 2434 - 2441.
[Abstract] [Full Text] [PDF]

Home page
 American Journal of Medical QualityHome page
C.-R. Chien and M.-S. Lai
Trends in the Pattern of Care for Lung Cancer and Their Correlation With New Clinical Evidence: Experiences in a University-Affiliated Medical Center
American Journal of Medical Quality, November 1, 2006; 21(6): 408 - 414.
[Abstract] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. R. Jett and Y. E. Miller
Update in lung cancer 2005.
Am. J. Respir. Crit. Care Med., April 1, 2006; 173(7): 695 - 697.
[Full Text] [PDF]

Home page
 JNMHome page
T. Bunyaviroch and R. E. Coleman
PET Evaluation of Lung Cancer
J. Nucl. Med., March 1, 2006; 47(3): 451 - 469.
[Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
P H Jarritt, A R Hounsell, K J Carson, D Visvikis, V P Cosgrove, J C Clarke, D P Stewart, V A L Fleming, R L Eakin, and A Zatari
Use of combined PET/CT images for radiotherapy planning: initial experiences in lung cancer
Br. J. Radiol., November 1, 2005; Supplement_28(1): 33 - 40.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2005 American Thoracic Society 		  New Orleans Int'l Conf